ArticleFrontiers in oncology2021
Case Report: Successful Treatment of Cutaneous Squamous Cell Carcinoma in Three Patients With a Combination of Acitretin and Clarithromycin.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing link prediction in biomedical knowledge graphs with BioPathNet.Nature biomedical engineering · 2026Article
- The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.International journal of molecular sciences · 2022Review
- Squamous Cell Carcinoma of the Nail Unit After Trauma: A Case Report.Clinical, cosmetic and investigational dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few studies have evaluated acitretin as a primary treatment for cutaneous squamous cell carcinoma (CSCC). We report, for the first time, three cases of CSCC successfully treated with acitretin and clarithromycin. A literature review on this subject was also was performed. This case report included three patients with CSCC treated with acitretin and clarithromycin at the First Affiliated Hospital of Fujian Medical University (2008-2019). Patient 1 (83-year-old woman, ulcerated mass on the left cheek), patient 2 (97-year-old woman, painful mass on the left cheek) and patient 3 (76-year-old woman, large mass on the right ankle) received 8, 6, and 30 courses of combination therapy. All patients tolerated the adverse effects (pseudotumor cerebri and mucocutaneous dryness) and achieved complete regression within 6 months. Patients 1, 2, and 3 have not experienced recurrence during a 10-, 3-, and 6-year follow-up. Acitretin has limited efficacy as a monotherapy for CSCC. Our experience indicates that combination therapy with acitretin and clarithromycin may be an effective and well-tolerated treatment for unresectable CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.